TrialNeurology2021

Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study.

Jacqueline A French et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.